Medline (NASDAQ:MDLN – Get Free Report) saw unusually large options trading activity on Wednesday. Stock traders acquired 10,954 call options on the company. This is an increase of approximately 289% compared to the typical daily volume of 2,819 call options.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on MDLN shares. Evercore set a $39.00 price target on shares of Medline in a research note on Thursday, August 6th. Citigroup upped their target price on shares of Medline from $45.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Leerink Partners upped their price target on shares of Medline from $43.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Zacks Research lowered Medline from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $47.00 price target on shares of Medline in a research note on Thursday, August 6th. Twenty-three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $46.08.
Read Our Latest Report on MDLN
Medline Stock Performance
Shares of Medline stock traded up $1.09 on Wednesday, reaching $38.77. 24,834,164 shares of the company were exchanged, compared to its average volume of 7,872,284. Medline has a 1-year low of $31.37 and a 1-year high of $50.88. The firm has a market cap of $50.99 billion and a price-to-earnings ratio of 87.78. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.51 and a current ratio of 4.04. The company’s 50-day moving average is $35.39 and its two-hundred day moving average is $39.31.
Medline (NASDAQ:MDLN – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.12. The firm had revenue of $7.86 billion for the quarter. Medline had a net margin of 1.84% and a return on equity of 8.21%. As a group, research analysts expect that Medline will post 1.58 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, major shareholder Private Ltd Gic sold 2,088,987 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $35.05, for a total value of $73,218,994.35. Following the completion of the sale, the insider directly owned 16,453,806 shares of the company’s stock, valued at $576,705,900.30. The trade was a 11.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 6,348,676 shares of company stock valued at $224,525,137 over the last three months. 0.81% of the stock is owned by insiders.
Institutional Investors Weigh In On Medline
Several institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC raised its stake in shares of Medline by 68.3% during the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock worth $25,000 after purchasing an additional 254 shares in the last quarter. Reyes Financial Architecture Inc. acquired a new stake in shares of Medline during the 3rd quarter worth approximately $30,000. NewEdge Advisors LLC boosted its position in shares of Medline by 100.0% during the 2nd quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock valued at $37,000 after acquiring an additional 475 shares in the last quarter. Allworth Financial LP grew its position in Medline by 86.2% in the second quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock valued at $41,000 after acquiring an additional 487 shares during the period. Finally, Flputnam Investment Management Co. acquired a new stake in shares of Medline during the third quarter worth approximately $43,000.
Medline Company Profile
Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.
Further Reading
- Five stocks we like better than Medline
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.
